SLNO Under Scrutiny: Pomerantz Law Firm Launches Investigation into Soleno Therapeutics Amid Vykat XR Safety Concerns

Investigation Targets Vykat XR Product Safety and Pricing

Pomerantz LLP has begun investigating Soleno Therapeutics (NASDAQ: SLNO) and its leadership following allegations regarding Vykat XR—Soleno's flagship (and only) product. These concerns were amplified after Scorpion Capital released a critical report on August 15, 2025, describing the medication as overpriced and potentially unsafe for children.

Recent Report Triggers Volatility in SLNO Stock

The fallout from the Scorpion Capital report was swift: SLNO shares dropped by $5.73, or 7.41%, closing at $71.63 on August 15, 2025. Although the company has seen significant price moves since, this episode has drawn renewed scrutiny to both the company's leadership and business practices. The ongoing legal investigation centers on whether Soleno or its executives may have committed securities fraud or engaged in unlawful conduct.

Legal Action Adds New Layer of Uncertainty for Investors

Pomerantz LLP, recognized for its track record in securities and antitrust litigation, urges Soleno investors to come forward if they have information related to the case. The firm's focus is on identifying potential securities fraud or other violations of fiduciary duty, which could have broad implications for the company and its investors if substantiated.

What Should SLNO Investors Watch Next?

With both the class-action law firm and a notable short-seller raising alarms, SLNO investors are left in a precarious spot. The coming weeks may bring further volatility as more details emerge from the investigation and the company's response to both legal and product safety challenges. For those tracking SLNO, this could be a pivotal period that determines the long-term trajectory of Soleno's business and reputation.

For further information or to participate in the investigation, investors are advised to contact Danielle Peyton at Pomerantz LLP via dpeyton@pomlaw.com or 646-581-9980, ext. 7980.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI